Augmentation of the anticancer effects of proteasome inhibitors by combination with sodium butyrate in human colorectal cancer cells

Experimental and Therapeutic Medicine

Volumn 1, Issue 4, 2010, Pages 675-693

  Abaza, M S I ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Apoptosis induction; Cell cycle modulation; Colorectal cancer; Growth inhibition; Proteasome inhibitors; Sodium butyrate; Synergy

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BUTYRIC ACID; CASPASE 3; CYTOCHROME C; EPOXOMICIN; LAMIN B; MG 115; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PSI 1; PSI 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL LEVEL; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME METABOLISM; HUMAN; HUMAN CELL; MITOCHONDRION; PROTEIN CLEAVAGE; PROTEIN SECRETION;

EID: 80855144452     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000106     Document Type: Article

References (75)

1. Mani A and Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23: 4776-4789, 2005.
2. Bowerman B and Kurz T: Degrade to create: developmental requirements for ubiquitin-mediated proteolysis during early C. elegans embryogenesis. Development 133: 773-784, 2006.
3. Naujokat C and Hoffmann S: Role and function of the 20S proteasome in proliferation and apoptosis. Lab Invest 82: 965-980, 2002.
4. Collins GA and Transey WP: The proteasome: a utility for transcription. Current Opin Genet Dev 16: 197-202, 2006.
5. Tylor C and Jobin C: Ubiquitin protein modification and signal transduction: Implications for inflammatory bowel diseases. Inflamm Bowel Dis 11: 1097-1107, 2005.
6. Asher G, Bercovich Z, Tsvetkov P, Shaul Yand Kahana C: 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. Mol Cell 17: 645-655, 2005.
7. Strehl B, Seifert U, Krüger E, Heink S, Kuckelkorn U and Kloetzel PM: Interferon-γ, the functional plasticity of the ubiquitin-proteasome system, and MHCclass Iantigen processing. Immunol Rev 207: 19-30, 2005.
8. Sakai N, Sawada MT and Sawada H: Non-traditional roles of ubiquitin-proteasome system in fertilization and gametogenesis. Int J Biochem Cell Biol 36: 776-784, 2004.
9. Heinemeyer W, Kleinschmidt JA, Saidowsky J, Escher C and Wolf DH: Proteinase yscE, the yeast proteasome/multicatalytic-multifunctional proteinase: Mutant unravels its function in stress proteolysis and uncovers its necessity for cell survival. EMBO J 10: 555-562, 1991.
10. Shinohara K, Tomioka M, Nakano H, Toné S, Ito H and Kawashima S: Apoptosis induction resulting from proteasome inhibition. Biochem J 317: 385-388, 1996.
11. Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet J and Magdelenat H: The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo and radioresistant human lymphocytic leukemia lymphocytes to TNF-α initiated apoptosis. Br J Cancer 77: 1103-1107, 1998.
12. Ma MH, Yang HH, Parker K, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9: 1136-1144, 2003.
13. Teicher BA: Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 14: 1610-1617, 2008.
14. Rajkumar SV, Richardson PG, Hideshima T and Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23: 630-639, 2005.
15. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP and Boise LH: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107: 4907-4919, 2006.
16. Velazquez OC, Lederer HM and Rombeau JL: Butyrate and the colonocyte: production, absorption, metabolism, and therapeutic implications. Adv Exp Med Biol 427: 123-134, 1997.
17. Macfarlane GT and Gibson GR: Microbiological aspects of the production of short-chain fatty acids in the large bowel. In: Physiological and Clinical Aspects of Short-Chain Fatty Acids. Cambridge University Press, Cambridge, pp87-105, 1995.
18. Pouillart PR: Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. Life Sci 63: 1739-1760, 1998.
19. Kruth J, Defer N and Tichonicky L: Molecular and cellular action of butyrate. CRSeances Soc Biol Fil 186: 12-25, 1992.
20. Velazquez OC and Rombeau JL: Butyrate: potential role in colon cancer prevention and treatment. Adv Exp Med Biol 427: 169-181, 1997.
21. Abaza MSI, Bahman Aand Al-Attiyah R: Roscovitine synergizes with conventional chemotherapeutic drugs to induce efficient apoptosis of human colorectal cancer cells. World J Gasteroenterol 14: 5162-5175, 2008.
22. Lam PK, To EW, Chan ES, Liew CT, Lung IW and King WK: In vitro modulation of head and neck cell growth by human recombinant interferon α and 13-cis-retinoic acid. Br J Biomed Sci 58: 226-229, 2001.
23. Abaza MSI, Al-Saffar AM, Al-Sawan SMand Al-Attiyah R: c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumor Biol 29: 287-303, 2008.
24. Fan XM, Wong BC, Wang WP, et al: Inhibition of proteasome function induced apoptosis in gastric cancer. Int J Cancer 93: 481-488, 2001.
25. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T, Jones DP and Wang X: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997.
26. Wilson MR: Apoptosis: unmasking the executioner. Cell Death Differ 5: 646-652, 1998.
27. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998.
28. Schendel SL, Montal M and Reed JC: Bcl-2 family proteins as ion-channels. Cell Death Diff 5: 372-380, 1998.
29. Lee S, Christakos S and Small MB: Apoptosis and signal transduction: clues to a molecular mechanisms. Curr Opin Cell Biol 5: 286-289, 1993.
30. Lopes UG, Erhardt P, Yao Rand Cooper GM: p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272: 12893-12896, 1997.
31. Blagosklonny MV, Wu GS, Omura S and El-Deriry WS: Proteasome-dependent regulation of p21Waf1/Cip1 expression. Biochem Biophys Res Commun 227: 564-569, 1996.
32. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995.
33. Orlowski RZ: The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Diff 6: 303-313, 1999.
34. Finucane DM, Wetzel-Bossy E, Waterhouse NJ, Cotter TG and Green DR: Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-XL. J Biol Chem 274: 2225-2233, 1999.
35. Ciechanover A: Proteolysis from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6: 79-87, 2005.
36. Admas J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349-360, 2004.
37. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethsome for relapsed multiple myeloma. NEngl J Med 352: 2487-2498, 2005.
38. Goy A, Younes A, McLaughlin P, et al: Phase IIstudy of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23: 667-675, 2005.
39. Hacihanefioglu A, Tarkun P and Gonullu E: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol 88: 219-222, 2008.
40. Enrico O, Gabriele B, Nadia C, et al: Unexpected cardiotoxicity in haematological bortezomib-treated patients. Br J Haematol 138: 396-397, 2007.
41. Richardson PG, Briemberg H, Jagannath S, et al: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24: 3113-3120, 2006.
42. Lonial S, Waller EK, Richardson PG, et al: Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106: 3777-3784, 2005.
43. Papandreou CN, Daliani DD, Nix D, et al: Phase Itrial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22: 2108-2121, 2004.
44. McConkey D and Zhu K: Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updates 11: 164-179, 2008.
45. Andrews PA and Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cell 2: 35-43, 1990.
46. Miller AA, Kurschel E, Osieka P and Schmidt CG: Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 23: 1283-1287, 1987.
47. Giuliano M, Lauricella M, Calvaruso G, Carabillo M, Emanuele S, Vento R and Tesoriere G: The apoptotic effects and synergistic interaction of sodium butytrate and MG132 in human retinoblastoma Y79 cells. Cancer Res 59: 5586-5595, 1999.
48. Kim OH, Lim JH, Woo KJ, Kim YH, Jin IN, Han ST, Park JW and Kwon TK: Influence of p53 and p21waf1 expression on G2/Mphase arrest of colorectal carcinoma HCT116 cells to proteasome inhibitors. Int J Oncol 24: 935-941, 2004.
49. Wu WK, Sung JY, Wu YC, Li ZJ, Yu L and Cho CH: Bone morphogenetic protein signaling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. Br J Pharmacol 154: 632-638, 2008.
50. Denlinger CE, Keller MD, Mayo MW, Broad RM and Jones DR: Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg 127: 1087-1086, 2004.
51. Abramova M, Pospelova TV, Nikulenkov FP, Hollander CM, Fornace AJ Jr and Pospelov VA: G1/S arrest induced by deacetylase inhibitor sodium butyrate in E1A+Ras-transformed cells is mediated through down-regulation of E2F activity and stabilization of β-catenin. J Biol Chem 281: 21040-21051, 2006.
52. Lauricella M, Calvaruso G, Giuliano M, Carabillo M, Emanuele S and Vento R: Synergistic cytotoxic interactions between butyrate, MG132 and camptothecin in human retinoblastoma Y79 cells. Tumor Biol 21: 337-348, 2000.
53. Kitagawa H, Tani E, Ikemoto H, Ozaki I, Nakano A and Omura S: Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett 443: 181-186, 1999.
54. Katayose Y, Kim M, Rakkar ANS, Li Z, Cowan KH and Seth P: Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 57: 5441-5446, 1997.
55. Timmerbeul I, Garrett-Engele CM, Kossatz U, et al: Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc Natl Acad Sci USA103: 14009-14014, 2006.
56. Pandit B and Gartel AL: New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer. Prostate 70: 825-833, 2010.
57. Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA and Anderson KC: Combination of novel proteasome inhibitor NPI-5552 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 115: 834-845, 2009.
58. Matondo M, Bousquet-Dubouch MP, Gallay N, et al: Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: Acorrelation with proteasome status. Leuk Res 34: 498-506, 2009.
59. Yuan JY, Shaham S, Ledoux S, Ellis HM and Horvitz HR: The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 75: 641-652, 1993.
60. Nicholson DW and Thornberry NA: Caspases: killer proteases. Trends Biochem Sci 22: 299-306, 1997.
61. Talanian RV, Quinlan C, Trautz S, et al: Substrate specificities of caspase family proteases. J Biol Chem 272: 9677-9682, 1997.
62. Fuchs E and Weber K: Intermediate filaments: structure, dynamics, function, and disease. Ann Rev Biochem 63: 345-382, 1994.
63. Germain M, Affar EB, D'Amours D, Dixit VM, Salvesen GS and Poirier GG: Cleavage of auto-modified poly(ADP-ribose)polymerase during apoptosis. Evidence for involvement of caspase-7. J Biol Chem 274: 28379-28384, 1999.
64. Cuvillier O, Rosenthal DS, Smulson ME and Spiegel S: Shingosine-1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas and ceramide-mediated apoptosis in Jurkat lymphocytes. J Biol Chem 273: 29010-29016, 1998.
65. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
66. Liu X, Kim CN, Yang J, Jemmerson R and Wang X: Induction of apoptotic program in cell-free extracts: requirement for dATPand cytochrome c. Cell 96: 147-157, 1999.
67. Chandra J, Niemer I, Gilbreath J, et al: Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 92: 4220-4229, 1998.
68. Chen YR, Wang X, Templeton D, Davis RJ and Tan TH: The role of c-jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet Cand λ radiation. J Biol Chem 31929-31936, 1996.
69. Williams SA and McConkey DJ: The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 63: 7338-7344, 2003.
70. Medina V, Edmonds B, Young GP, James R, Appleton S and Zalewski PD: Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin-A(inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 57: 3697-3707, 1997.
71. Lara PN, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH and Gandara DR: Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Sem Oncol 31: 40-46, 2004.
72. Zhu H, Zhang L, Dong F, et al: Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 24: 4993-4999, 2005.
73. Goldstein JC, Waterhouse NJ, Juin P, Evan GI and Green DR: The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2: 156-162, 2000.
74. Daly K and Shirazi-Beechey SP: Microarray analysis of butyrate-regulated genes in colonic epithelial cells. DNACell Biol 25: 49-62, 2006.
75. Davie JR: Inhibition of histone deacetylase activity by butyrate. J Nutr 133 (suppl 7): 2485-2493, 2003.